BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 31667733)

  • 1. Increased
    Koyasu S; Shimizu Y; Morinibu A; Saga T; Nakamoto Y; Togashi K; Harada H
    J Neurooncol; 2019 Dec; 145(3):441-447. PubMed ID: 31667733
    [TBL] [Abstract][Full Text] [Related]  

  • 2. IDH-wildtype glioblastomas and grade III/IV IDH-mutant gliomas show elevated tracer uptake in fibroblast activation protein-specific PET/CT.
    Röhrich M; Loktev A; Wefers AK; Altmann A; Paech D; Adeberg S; Windisch P; Hielscher T; Flechsig P; Floca R; Leitz D; Schuster JP; Huber PE; Debus J; von Deimling A; Lindner T; Haberkorn U
    Eur J Nucl Med Mol Imaging; 2019 Nov; 46(12):2569-2580. PubMed ID: 31388723
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Radiolabeled inhibitors as probes for imaging mutant IDH1 expression in gliomas: Synthesis and preliminary evaluation of labeled butyl-phenyl sulfonamide analogs.
    Chitneni SK; Reitman ZJ; Gooden DM; Yan H; Zalutsky MR
    Eur J Med Chem; 2016 Aug; 119():218-30. PubMed ID: 27163884
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Less Invasive Phenotype Found in Isocitrate Dehydrogenase-mutated Glioblastomas than in Isocitrate Dehydrogenase Wild-Type Glioblastomas: A Diffusion-Tensor Imaging Study.
    Price SJ; Allinson K; Liu H; Boonzaier NR; Yan JL; Lupson VC; Larkin TJ
    Radiology; 2017 Apr; 283(1):215-221. PubMed ID: 27849434
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A high-sensitive HMab-2 specifically detects IDH1-R132H, the most common IDH mutation in gliomas.
    Fujii Y; Ogasawara S; Oki H; Liu X; Kaneko MK; Takano S; Kato Y
    Biochem Biophys Res Commun; 2015 Oct; 466(4):733-9. PubMed ID: 26381180
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Radioprotection of IDH1-Mutated Cancer Cells by the IDH1-Mutant Inhibitor AGI-5198.
    Molenaar RJ; Botman D; Smits MA; Hira VV; van Lith SA; Stap J; Henneman P; Khurshed M; Lenting K; Mul AN; Dimitrakopoulou D; van Drunen CM; Hoebe RA; Radivoyevitch T; Wilmink JW; Maciejewski JP; Vandertop WP; Leenders WP; Bleeker FE; van Noorden CJ
    Cancer Res; 2015 Nov; 75(22):4790-802. PubMed ID: 26363012
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthesis and evaluation of radiolabeled AGI-5198 analogues as candidate radiotracers for imaging mutant IDH1 expression in tumors.
    Chitneni SK; Reitman ZJ; Spicehandler R; Gooden DM; Yan H; Zalutsky MR
    Bioorg Med Chem Lett; 2018 Feb; 28(4):694-699. PubMed ID: 29366652
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The prognostic IDH1( R132 ) mutation is associated with reduced NADP+-dependent IDH activity in glioblastoma.
    Bleeker FE; Atai NA; Lamba S; Jonker A; Rijkeboer D; Bosch KS; Tigchelaar W; Troost D; Vandertop WP; Bardelli A; Van Noorden CJ
    Acta Neuropathol; 2010 Apr; 119(4):487-94. PubMed ID: 20127344
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of Immunohistochemical Expression of ALK-1 in Gliomas, WHO Grade 4 and Its Correlation with IDH1-R132H Mutation Status.
    Khairy RA; Momtaz EM; Abd El Aziz AM; Shibel PEE
    Asian Pac J Cancer Prev; 2024 Jan; 25(1):317-323. PubMed ID: 38285799
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas.
    Hartmann C; Hentschel B; Wick W; Capper D; Felsberg J; Simon M; Westphal M; Schackert G; Meyermann R; Pietsch T; Reifenberger G; Weller M; Loeffler M; von Deimling A
    Acta Neuropathol; 2010 Dec; 120(6):707-18. PubMed ID: 21088844
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The diagnostic value of lower glucose consumption for IDH1 mutated gliomas on FDG-PET.
    Liu FM; Gao YF; Kong Y; Guan Y; Zhang J; Li SH; Ye D; Wen W; Zuo C; Hua W
    BMC Cancer; 2021 Jan; 21(1):83. PubMed ID: 33472598
    [TBL] [Abstract][Full Text] [Related]  

  • 12. IDH1 R132H mutation generates a distinct phospholipid metabolite profile in glioma.
    Esmaeili M; Hamans BC; Navis AC; van Horssen R; Bathen TF; Gribbestad IS; Leenders WP; Heerschap A
    Cancer Res; 2014 Sep; 74(17):4898-907. PubMed ID: 25005896
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical prognostic value of the isocitrate dehydrogenase 1 single-nucleotide polymorphism rs11554137 in glioblastoma.
    Mistry AM; Vnencak-Jones CL; Mobley BC
    J Neurooncol; 2018 Jun; 138(2):307-313. PubMed ID: 29423539
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Induction of synthetic lethality in IDH1-mutated gliomas through inhibition of Bcl-xL.
    Karpel-Massler G; Ishida CT; Bianchetti E; Zhang Y; Shu C; Tsujiuchi T; Banu MA; Garcia F; Roth KA; Bruce JN; Canoll P; Siegelin MD
    Nat Commun; 2017 Oct; 8(1):1067. PubMed ID: 29057925
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative evaluation of
    Norikane T; Mitamura K; Yamamoto Y; Manabe Y; Murao M; Arai-Okuda H; Hatakeyama T; Miyake K; Nishiyama Y
    J Neurooncol; 2024 Jan; 166(1):195-201. PubMed ID: 38160415
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Isocitrate Dehydrogenase Mutations are Better Prognostic Marker than O6-methylguanine-DNA Methyltransferase Promoter Methylation in Glioblastomas - a Retrospective, Single-centre Molecular Genetics Study of Gliomas.
    Houdova Megova M; Drábek J; Dwight Z; Trojanec R; Koudeláková V; Vrbková J; Kalita O; Mlcochova S; Rabcanova M; Hajdúch M
    Klin Onkol; 2017; 30(5):361-371. PubMed ID: 29031038
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Secondary Glioblastoma: Molecular and Clinical Factors That Affect Outcome After Malignant Progression of a Lower Grade Tumor.
    Gessler F; Zappi J; Konczalla J; Bernstock JD; Forster MT; Wagner M; Mittelbronn M; Seifert V; Senft C
    World Neurosurg; 2017 Jun; 102():49-55. PubMed ID: 28263929
    [TBL] [Abstract][Full Text] [Related]  

  • 18. R132H mutation in IDH1 gene reduces proliferation, cell survival and invasion of human glioma by downregulating Wnt/β-catenin signaling.
    Cui D; Ren J; Shi J; Feng L; Wang K; Zeng T; Jin Y; Gao L
    Int J Biochem Cell Biol; 2016 Apr; 73():72-81. PubMed ID: 26860959
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Isocitrate dehydrogenase type I mutation as a prognostic factor in glioblastoma and a literature review].
    de Quintana-Schmidt C; Alvarez-Holzapfel MJ; Nomdedeu-Guinot J; Bague-Rosell S; Gallego-Rubio O; Leidinger A; Salgado-Lopez L; Molet-Teixidó J
    Neurocirugia (Astur); 2015; 26(6):276-83. PubMed ID: 26194445
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Isocitrate dehydrogenase1 mutation reduces the pericyte coverage of microvessels in astrocytic tumours.
    Sun C; Zhao Y; Shi J; Zhang J; Yuan Y; Gu Y; Zhang F; Gao X; Wang C; Wang Y; Wang Z; Hu P; Qin J; Xiao L; Chang T; Wang L; Xi Y; Yin H; Chen H; Zhang L; Cheng G; Lin J; Zhang M; Li Z; Ye J
    J Neurooncol; 2019 Jun; 143(2):187-196. PubMed ID: 31004262
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.